Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 15;3 Suppl 1(Suppl 1):S25.
doi: 10.1186/1746-1596-3-S1-S25.

Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study

Affiliations

Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study

Isidro Machado et al. Diagn Pathol. .

Abstract

Background: Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter results mainly from the malignant transformation of a benign pre-existing tumour.

Methods: All the cases diagnosed as Chs (primary tumours, recurrences and/or metastasis and xenotransplanted Chs) from the files of our Department were collected. Only cases with paraffin blocks available were selected (Total 32 cases). Six Tissue Microarrays (TMAs) were performed and all the cases and biopsies were distributed into the following groups: a) only paraffin block available from primary and/or metastatic tumours (3 TMAs), b) paraffin block available from primary and/or metastatic tumours as well as from the corresponding Nude mice xenotransplant (2 TMAs), c) only paraffin block available from xenotransplanted Chs (1 TMA). A reclassification of all the cases was performed; in addition, conventional hematoxylin-eosin as well as immunohistochemistry staining (S100, SOX-9, Ki-67, BCL-2, p53, p16, CK, CD99, Survivin and Caveolin) was analyzed in all the TMA.

Results: The distribution of the cases according to the histopathological pattern and the location of tumours were as follows: fourteen Grade I Chs (all primaries), two primary Grade II Chs, ten Grade III Chs (all primaries), five dedifferentiated Chs (four primaries and one primary with metastasis), and two Chs from cell cultures (Ch grade III). One recurrent extraskeletal myxoid Chs was included as a control in the TMA. Although there was heterogeneity in immunohistochemistry results of the different material analyzed, S100, SOX-9, Caveolin and Survivin were more expressed. The number of passages in xenotransplants fluctuated between 1 and 13. Curiously, in Grade I Chs, these implanted tumours hardly grew, and the number of passages did not exceed one.

Conclusion: The study of Chs by means of TMA techniques is very important because it will improve the assessment of different antibodies applied in the immunohistochemical assays. Xenotransplanted tumours in TMA improve knowledge concerning the variability in the morphological pattern shown by these tumours during the evolution in nudes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathology and IHC profile in Chs.
Figure 2
Figure 2
Dedifferentiated Ch, Original Tumour.
Figure 3
Figure 3
Nude 385 Passage 0.
Figure 4
Figure 4
Nude 385 Passage 1.
Figure 5
Figure 5
Nude 385 Passage 2.
Figure 6
Figure 6
Nude 385 Passage 3.

Similar articles

Cited by

References

    1. Hassan S, Ferrario C, Mamo A, Basik M. Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol. 2007 - PubMed
    1. Kramer MW, Merseburger AS, Hennenlotter J, Kuczyk M. Tissue microarrays in clinical urology – Technical considerations. Scand J Urol Nephrol. 2007. pp. 1–7. - PubMed
    1. Merseburger AS, Anastasiadis AG, Hennenlotter J, Schilling D, Simon P, Machtens SA, Serth J, Stenzl A, Kuczyk MA. Tissue microarrays: applications in urological cancer research. World J Urol. 2006;24:579–584. doi: 10.1007/s00345-006-0103-1. - DOI - PubMed
    1. Merseburger AS, Hennenlotter J, Schilling D, Sievert KD, Kufer R, Kuczyk MA. Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma. Urologe A. 2006;45:323–324. doi: 10.1007/s00120-006-1005-y. 326–327. - DOI - PubMed
    1. Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep. 2003;10:223–228. - PubMed